增生平对口腔癌预防作用的实验和临床研究  

Experimental and clincal study on Zengshengping's preventive effect on oral cancer

作　　者：孙正[1] 李宁[2] 刘晓勇[1] 王荣[1] 

机构地区：[1]首都医科大学口腔医学院,北京100050 [2]中国疾病预防控制中心营养与食品安全所

出　　处：《北京口腔医学》2005年第3期168-171,共4页Beijing Journal of Stomatology

摘　　要：目的观察增生平对二甲基苯蒽(dimethyl-benzanthracene,DMBA)诱发的金黄地鼠口腔癌的阻断作用和对口腔癌前病变一口腔粘膜白斑的治疗效果.方法实验室研究50只雄性金黄地鼠,随机分为3组,阴性对照组10只,仅涂丙酮液.增生平治疗组和DMBA组各20只动物.DMBA组涂0.5%DMBA丙酮液,每周3次,共涂6周,治疗组DMBA同样处理后,每天给地鼠灌胃6.Og/kg剂量的增生平,治疗10周,进行肉眼和病理观察,同时进行微核、银染核仁组织区(Argentums Nucleolar Organizer Regions,AgNOR)和细胞增殖抗原(Proliferation Cell Nuclear Antigen,PCNA)检测.临床研究112名经临床和病理检查诊断为口腔粘膜白斑的患者随机分为治疗组59名和对照组53名.治疗组服用增生平,3次/日,每次4片,治疗8～12个月,对照组定期观察.治疗期间观察白斑病损变化.结果动物实验增生平组平均瘤数目和瘤负荷显著低于DMBA组,其抑制率分别为44.6%和69.6%,癌变率为55.0%,显著低于阳性对照组95.0%,实验组细胞微核发生率、AgNOR数目和PCNA标记指数均显著低于阳性对照组.临床治疗组有67.8%的患者白斑病损缩小,而对照组仅16.9%的患者白斑病损缩小.结论增生平可以使口腔癌前病变逆转,降低口腔癌的发生率.增生平对口腔粘膜白斑有一定的治疗作用.Objective To study and observe the preventive effect of Zengshengping on DMBA-induced hamster oral carcinogenesis and the clinical effect of Zengshengping on human oral leukoplakia, the precancerous lesion of oral cancer. Methods In experimental study, 50 male hamsters were randomly divided into 3 groups, the negative control group （ 10 hamsters） , the Zengshengping treated group （20 hamsters） and the DMBA group （20 hamsters）. The negative control group was only treated with acetone, the DMBA group treated with 0. 5% DMBA three times per week for 6 weeks, the Zengshengping treated group treated with Zengshengping 6. 0g/kg per day for 10 weeks after being treated the same as the DMBA group, and then observed visually and pathologically. At the same time, micronucleus, argentum nucleolar organizer regions（AgNOR） , proliferation cell nuclear antigen（ PCNA ）were examined. In clinical study, 112 patients with oral leukoplakia were randomly divided into two groups： treated group and 59 for the control group 53. The treated group was administered with Zengshengping 4 tablets each time and 3 times per day for 8 to 12 months; The control group was observed without treatment. Results The average tumor number and tumor burden of the treated group was remarkably lower than that of the DMBA group with the inhibition rate of 44. 6% and 69.6% respectively. The canceration rate was 55.0% ,much lower than 95.0% for the positive control group. Incidence of micronucleated cell, AgNOR number and PCNA labeling index of the treated group was evidently lower than that of the positive control group. The size of oral lesion decreased in 67. 8% of the patients in the treated group while only 16.9% in the placebo treatment group. Conclusion Zengshengping may revert and cure the precancerous lesion and lower the incidence rate of oral cancer. Zengshengping has certain therapeutic effects on the oral leukoplakia.

关 键 词：增生平 口腔粘膜白斑 口腔癌 预防 

分 类 号：R739.8[医药卫生—肿瘤]